Skip to content

Humane Genomics

YC S21 · Active · A platform to make artificial viruses as cancer therapeutics.

Competitors

Adjacent

Also from S21

All of S21

About Humane Genomics

Humane Genomics has developed a platform to engineer cancer killing viruses. We have taken a first principles approach to design and make oncolytic viral therapies. Using a highly lytic RNA virus engineered with "2 factor authentication" (using selective infection and selective replication) they have an on-target to off-target kill ratio > 1000. We are working on our first indication, pediatric liver cancer (hepatoblastoma), with our partners at Texas Children's Hospital, who are world leading experts. We have in vivo (mouse) data showing safety and currently developing efficacy data and are showing 50% reduction in tumor volume.

YC batch
S21 · Summer 2021
Status, per YC
Active
Category
Other
Team size
5
Location
New York City, NY, USA; New York, NY, USA
Checked
34m ago

YC tags: Hard Tech, Synthetic Biology

Humane Genomics in S21: 391 companies, 34% AI

Humane Genomics: questions

Which YC batch was Humane Genomics in?

Humane Genomics was in Y Combinator's Summer 2021 batch (S21).

Is Humane Genomics still active?

Y Combinator lists Humane Genomics as active.

Where is Humane Genomics based?

Humane Genomics lists New York City, NY, USA; New York, NY, USA as its location on YC's directory.

Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.

New startups by email

Mondays: new YC data, AI and devtools companies and status changes, only when something changed.

Double opt-in. Unsubscribe any time.